Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Servier unveils its 2030 ambition and reveals a new visual identity

* A new ambition by 2030 to accelerate its transformation dynamic * A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal PARIS, Oct. 6, 2022 /PRNewswire/ -- Servier today unveils its 2030 ambition as well as a new visual identity that reflec...

2022-10-06 13:30 1812

ASTRAZENECA, First Organization in Egypt receiving Best place to work for Millennials Award

CAIRO, Oct. 5, 2022 /PRNewswire/ -- AstraZeneca Egypt, was recently certified as a Best Place to Work for Millennials marking it the first organization in Egypt to receive such award. The certification is based on an HR analysis of the company policies focusing on Millennials and an anonymous emp...

2022-10-05 22:59 1026

Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH

-- ASC41 is ranking first in China and third in the world in terms of clinical progress as a thyroid hormone receptor β (THRβ) agonist drug candidate for non-alcoholic steatohepatitis (NASH). ASC41 Phase II clinical trial is currently the most advanced 52-week Phase II clinical trial which is in...

2022-10-05 08:10 2236

Transcenta Received IND Clearance from FDA for Its Best-In-Class MASP2 Targeting Antibody TST004 for the Treatment of IgA Nephropathy

SUZHOU, China, Oct. 5, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that TST004, its best...

2022-10-05 08:00 1996

HAVAS HEALTH & YOU APPOINTS PAUL PFLEIDERER AS PRESIDENT OF HAVAS LIFE NEW YORK

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- As the rapid evolution of the health and wellness sector continues to necessitate innovative thinking and activation across the industry, Havas Health & You today announced that it has appointed seasoned strategic leaderPaul Pfleiderer as President of Havas ...

2022-10-04 21:00 1034

HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner

* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) * In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level * Batoclimab (form...

2022-10-04 19:00 1208

Hayashibara Brings Back "Trehalose Symposium" to Reveal Its Game-changing Versatilities in Human Biochemistry

OKAYAMA, Japan, Oct. 4, 2022 /PRNewswire/ -- Hayashibara Co., Ltd., a member of Nagase Group and headquartered in Okayama City, westernJapan, hosted the 24th Trehalose Symposium, with the support of the Japanese Society of Applied Glycoscience, onSeptember 8, 2022. Photo: https://kyodonewsprwir...

2022-10-04 14:00 1003

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research LAUSANNE, Switzerland, Oct. 3, 2022 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global bioph...

2022-10-03 15:00 1366

AeroRx Partners with HCmed to Develop a Nebulized LABA/LAMA Combination Solution for the Treatment of Chronic Obstructive Pulmonary Disease

TAIPEI, Oct. 2, 2022 /PRNewswire/ -- AeroRx Therapeutics, LLC. (AeroRx) and HCmed Innovations Co., Ltd. (HCmed) have initiated a collaboration, introducing a LABA/LAMA combination solution for delivery with a breath-actuated nebulizer. This collaboration sets forth the framework by which both com...

2022-10-03 09:00 1041

Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2022

JIUQUAN, China, Sept. 30, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the first six months of fiscal year 2022 endedMarch 31, 2022...

2022-10-01 04:30 4421

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2023

GOTHENBURG, Sweden, Oct.1, 2022 /PRNewswire/ -- Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee for the company's Annual General Meeting 2023 has been appointed. ...

2022-10-01 00:53 2489

YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.

* Transaction values YS Biopharma at pre-money equity value of $834 million * Certain investors ("Forward Purchase Investors") are expected to invest $30 million in a private placement concurrently with the closing of the business combination transaction pursuant to certain forward purchase ag...

2022-09-30 04:01 2463

First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent

MELBOURNE, Australia, Sept. 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose inNew Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known ...

2022-09-30 02:30 2004

Doxy.me extends telemedicine's reach to 88% of the world's population

Doxy.me adds over 100 languages, live interpreters, and global currencies to overcome barriers to telemedicine around the world. CHARLESTON, S.C., Sept. 30, 2022 /PRNewswire/ -- Doxy.me, the web-based telemedicine platform on a mission to make telemedicine available to all, is expanding its capa...

2022-09-29 22:03 1557

Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022

* Two distinctive platforms will streamline the antibody development process. * With an advanced design and high binding affinity, S-DUAL™ ensures optimized manufacturability of bispecific antibodies. * DEVELOPICK™ provides early insight and selection guidance to save time and cost to maxi...

2022-09-29 19:00 1103

NeuShen Therapeutics Closes Pre-A Financing with ~$20M

* Closure of pre-A financing round led by LAMPAM Capital * Dual internal discovery platforms of small molecule and AAV-based gene therapy targeting neurological and psychiatric disorders SHANGHAI, Sept. 29, 2022 /PRNewswire/ -- NeuShen Therapeutics, Inc., a biotechnology company focusing on d...

2022-09-29 17:50 1477

NeuShen Therapeutics Closes Pre-A Financing with ~$20M

Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC

SUZHOU, China, Sept. 29, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the results from a phase Ib study of pruxelutamide (used to be ...

2022-09-29 14:22 1142

Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc

* Simcere will receive a $15 million upfront payment, and up to $492 million in development and commercial milestone payments considering successful achievements in several indications, with an important part as sales milestones, as well as up to low double-digit tiered royalties based upon fu...

2022-09-29 11:32 1252

Zhongchao Inc. Establishes Chongqing Xinjiang Pharmaceutical Co., Ltd. to Improve Patient Access to Medications

SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the establishment of Chongqing Xinjiang Pharmaceutical Co., Ltd...

2022-09-28 21:18 1340

ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world

* ASTRUM-005 is the first study to demonstrate that PD-1 inhibitors plus chemotherapy can improve survival for patients with ES-SCLC. * In ASTRUM-005, serplulimab combined with chemotherapy achieved by far the longest OS in first-line immunotherapy for ES-SCLC. Compared with chemotherapy, the...

2022-09-28 21:00 1806

1 ... 107 108 109110111 112 113 ... 293